Table 2.
“I expect no major changes with the different formulations” n (%) |
Liquid solution n (%) |
Tablets n (%) |
Soft-gel capsules n (%) |
Tablets form another manufacturer n (%) |
|
---|---|---|---|---|---|
Interfering drugs may influence the stability of therapy. Which LT4 preparation is in your experience less likely to be subject to variable absorption? | 23(58.9%) | 4(10.3%) | 12 (30.8%) | 0 (0%) | 0 (0%) |
Which of the following preparations of LT4 would you prescribe in case of a first diagnosis of hypothyroidism, when the patient self-reports intolerance to various foods raising the possibility of celiac disease, malabsorption, lactose intolerance or intolerance to excipients? | 9 (23.1%) | 2 (5.1%) | 28 (71.8%) | 0 (0%) | 0 (0%) |
Which of the following preparations of LT4 would you prescribe for a patient established on generic LT4 who has unexplained poor biochemical control of hypothyroidism? | 23(58.9%) | 1(2.6%) | 0 (0%) | 1(2.6%) | 14(35.9%) |
Which of the following preparations of LT4 would you prescribe for a patient with poor biochemical control who is unable (due to busy lifestyle) to take LT4 fasting and separate from food/drink? | 19 (48.7%) | 2 (5.1%) | 16(41%) | 2 (5.1%) | 0 (0%) |
Which of the following preparations of LT4 would you prescribe for a patient established on generic T4 who has good biochemical control of hypothyroidism but continues to have symptoms? | 31 (79.5%) | 0 (0%) | 0 (0%) | 1(2.6%) | 7 (17.9%) |